

Page I of 2

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.usplo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/040,281

11/07/2001

Jeffrey L. Browning

B129USCP2DV2CO

Patent Administrator BIOGEN, INC. 14 Cambridge Center Cambridge, MA 02142 CONFIRMATION NO. 9658
FORMALITIES LETTER
OC00000008807514

Date Mailed: 09/18/2002

NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Filing Date Granted

The U.S. Patent and Trademark Office has received your reply on 05/28/2002 to the Notice to File Missing Parts (Notice) mailed 02/26/2002 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - The specification cannot be scanned or properly stored. Page(s)

o Papers must be legibly written either by a typewriter or mechanical printer in permanent ink or its equivalent in portrait orientation on flexible, strong, smooth, non-shiny, durable, and white paper. Application papers must be presented in a form having sufficient clarity and contrast between the paper and the writing thereon to permit the direct reproduction of readily legible copies in any number by use of photographic, electrostatic, photooffset, and microfilming processes and electronic reproduction by use of digital imaging and optical character recognition. Pages 94 are not in compliance with 37 CFR 1.52(a). The drawings filed are unacceptable because:

Replacement page(s), together with a statement that the replacement page(s) contain no new matter, are required.

• This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or

- 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



Docket: B129 USCP2DV2CN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Browning et al.

U.S. Serial No.:

10/040,281

Filing Date:

November 7, 2001

For:

Lymphotoxin-β, Lymphotoxin-β Complexes, Pharmaceutical

Preparations and Therapeutic Uses Thereof

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as Express Label No. EL798594013US in an Express Mail Envelope addressed to Box Missing Parts, Commissioner for

Patents, Washington, D.C. 20231 on the date shown below.

Date: 26 Left. 2003 Signature:

Jeanne S. Schmitter

Response to Notice of Incomplete Reply of a Nonprovisional Application

Box Missing Parts Commissioner for Patents, Washington, D.C. 20231

Sir:

In response to the Notice of Incomplete Reply of a Nonprovisional Application mailed September 18, 2002, Applicant hereby requests a five-month extension of time. Applicants previously submitted a Response to File Missing Parts on May 28, 2002 and paid for a onemonth extension of time and a surcharge of \$130.00 for a late filing fee. Therefore, Applicants believe that they owe a balance of \$1850.00 (\$1960-\$110).

Enclosed please find a substitute specification in compliance with 37 CFR 1.52; 18 sheets of drawings; Sequence Listing on paper and in computer readable form with Statement; Letter to the Chief Draftsperson with 18 pages of formal drawings, Figs. 1A-16B-4; copy of the Notice of Incomplete Reply (Nonprovisional).

Please charge our deposit account 02-2327, \$1850.00 as payment for a five-month extension of time and for any other deficiencies that may be necessary.

Date: 9-26-02

Respectfully submitted,

John T. Li

John T. Li

Reg. No. 44,210

BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 914-4704

PTO/SB/21 (6-98)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays valid OMB control number. Please type a plus sign (+) inside this box +

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 406

Typed or printed name

10/040,281 Application Number 11/07/2001 **Filing Date** Browning, Jeffrey et al. **First Named Inventor** 1635 Group Art Unit TBD **Examiner Name** B129USCP2DV2CN Attorney Docket Numbe

ENCLOSURES (check all that apply)								
Fee Transmittal Form		Assignment Papers (for an Application)		After Allowance Communication to Group				
Fee Attached		Drawing(s)			Appeal Communication to Board of Appeals and Interferences			
Amendment / Response		Licensing-related Papers			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition			Proprietary Information			
Affid	avits/declaration(s)		o Convert to a nal Application		Status Letter			
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Small Entity Statement		X	Additional Enclosure(s) (please identify below)			
Express Abandonment Request					Replacement Specification with Statement; Sequence Listing (paper and computer-readable form) with Statement; copy of			
			for Refund	ł	Notice of Incomplete Reply dated 9/18/02.			
Certified Copy of Priority Document(s)		Remarks						
Response to Missing Parts/ Incomplete Application								
Response to Missing Parts under 37 CFR 1.52 or 1.53								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm <i>or</i> Individual name	John T. Li, Reg. No. 44,210							
Signature	John T. Li							
Date	26 September 2002							

Signature Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 26 Sept. 2002

John T. Li



Docket No. B129 USCP2DV2CN

Applicant: J. Browning et al.

Serial No.: 10/040,281 Filing Date: 11/07/2001

For: Lymphotoxin-B, Lymphotoxin-B Complexes, Pharmaceutical Preparations And Therapeutic

Uses Thereof

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence:

Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

on 26 September 2002

Date

Jeanne Schmitter

SEP 2 6 2002

PTO/SB/17 (09-00)

Approved for use through 10/31/2002, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. ADDITIONAL FEES

Large Entity Small Entity Fee Fee Fee Fee Code (\$) Code (\$)

EE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

METHOD OF PAYMENT The Commissioner is hereby authorized to charge

indicated fees and credit any overpayments to:

TOTAL AMOUNT OF PAYMENT

02-2327

1. 🗶

Deposit

Account Number

(\$)185000

Complete if Known					
Application Number	10/040,281				
Filing Date	7 November 2001				
First Named Inventor	Browning, Jeffrey et al.				
Examiner Name	TBD				
Group Art Unit	1635				
Attorney Docket No.	B129USCP2DV2CN				

FEE CALCULATION (continued)

Fee Description

Fee Paid

Number 02-2321	105 130	205 65	Surcharge - late filing fee or oath			
Deposit Account Name	127 50	227 25	Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	139 130	139 130	Non-English specification			
Applicant claims small entity status.	147 2,520	147 2,520	For filing a request for ex parte reexamination			
See 37 CFR 1.27	112 920*	112 920*	Requesting publication of SIR prior to Examiner action			
2. Payment Enclosed: Check Credit card Money Order Other	113 1,840*	113 1,840	* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110	215 55	Extension for reply within first month			
1. BASIC FILING FEE	116 390	216 195	Extension for reply within second month			
Large Entity Small Entity	117 890	217 445	Extension for reply within third month			
Fee Fee Fee Fee Description	118 1,390	218 695	Extension for reply within fourth month			
Code (4) Code (4)	128 1,890	228 945	Extension for reply within fifth month	1850.		
,	119 310	219 155	Notice of Appeal			
106 320 206 160 Design filing fee	120 310	220 155	Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee 108 710 208 355 Reissue filing fee	121 270	221 135	Request for oral hearing			
	138 1,510	138 1,510	Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140 110	240 55	Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 0	141 1,240	241 620	Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1,240	242 620	Utility issue fee (or reissue)			
Fee from Extra Claims below Fee Paid	143 440	243 220	Design issue fee			
Total Claims	144 600	244 300	Plant issue fee			
Independent	122 130	122 130	Petitions to the Commissioner			
Claims	123 50	123 50	Petitions related to provisional applications			
	126 240	126 240	Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Fee Description	581 40	581 40	Recording each patent assignment per property (times number of properties)			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	146 710	246 355	Filing a submission after final rejection (37 CFR § 1.129(a))			
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	149 710	249 355	For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims over original patent	179 710	279 355	Request for Continued Examination (RCE)			
110 18 210 9 ** Reissue claims in excess of 20	169 900	169 900	Request for expedited examination of a design application			
and over original patent	Other fee (s	pecify)	o, a design approach			
SUBTOTAL (2) (\$) 0		,,,				
**or number previously paid, if greater; For Reissues, see above	*Reduced by	Basic Filing	Fee Paid SUBTOTAL (3) (\$)185	0.00		
SUBMITTED BY Complete (if applicable)						
Name (Print/Type) John T. Li		ration No. y/Agent)	44,210 Telephone (617) 914	-4704		
Signature John T. Li	•		Date 9-26-	02		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#10

U.S. Patent Application No. 10/040,281 Docket No. B129USCP2DV2CN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jeffrey L. Browning et al.

Serial No.:

10/040,281

Filing Date:

7 November 2001

For:

LYMPHOTOXIN-BETA, LYMPHOTOXIN-BETA COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office under CFR 1.10 as Express Mail Label No. <u>EL 798594013US</u> addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date:

26 Sept. 2000

Signature;

Jeanne S. Schmitter

STATEMENT REGARDING SUBSTITUTE SPECIFICATION

Box Missing Parts Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice of Incomplete Reply (Nonprovisional), Applicants hereby submits a substitute specification under 37 CFR 1.52. Applicants assert that there is no new matter included.

Please replace the previously submitted specification with the enclosed replacement specification.

Respectfully submitted,

Date: 9-26-02

John 4. Li

Reg. No. 44,210 BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142

(617) 914-4704